Sellas Life Sciences is now trading 4.1% down at $11.80, with no new company-specific announcement identified to explain the October 1 decline. - Recent buyout discussion was retail speculation, not a disclosed catalyst. - Broader markets faced pressure amid rising Treasury yields and concerns about inflation and the fiscal outlook, potentially weighing on risk appetite. Major indices fell less than 0.5%, so the evidence does not establish a direct market cause for the stock’s larger move.